NCT04246372View on ClinicalTrials.gov

Tofacitinib for Immune Skin Conditions in Down Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

October 21, 2020

Primary Completion Date

October 30, 2024

Study Completion Date

October 30, 2024

Conditions
Down SyndromeAlopecia AreataAtopic Dermatitis / EczemaHidradenitis SuppurativaVitiligoPsoriasis
Interventions
DRUG

Tofacitinib

Treatment with oral Tofacitinib for immune mediated skin conditions in adults with Down syndrome

Trial Locations (1)

80045

Linda Crnic Institute for Down Syndrome, Aurora

All Listed Sponsors
collaborator

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

lead

University of Colorado, Denver

OTHER

NCT04246372 - Tofacitinib for Immune Skin Conditions in Down Syndrome | Biotech Hunter | Biotech Hunter